Clinical Trials Logo

Clinical Trial Summary

This is a single arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans. FAZA PET-MRI will be used to measure hypoxia in up to 20 patients with unresectable, non-metastatic, locally advanced un-resectable pancreatic adenocarcinoma (LAPAC). After each FAZA PET-MRI scan, patients will be followed up via telephone, 48 hours after the imaging session to assure that the procedure was tolerated without side effects. Patients will undergo a FAZA PET-MRI scans before and after their standard of care radiation treatment.


Clinical Trial Description

The success of hypoxia-targeted therapies has so far been limited, a fact widely attributed to the absence of a reliable imaging biomarker for hypoxia that could easily be implemented into a routine clinical workflow. A compelling study has found the presence of hypoxia in pancreatic tumors using FAZA-PET imaging. The data derived from this alternative dual-imaging approach can be used to establish a patient-specific perfusion-to-hypoxia mapping, accounting for differences in tumour metabolisms. This technique was recently validated in a pre-clinical FAZA-PET/CE-MRI study of mice with orthotopically-implanted pancreatic patient-derived tumour xenografts. The purpose of this study is to look for hypoxia in tumours using a PET scan in combination with MRI. The use of PET/MRI scans to measure hypoxia may be better and simpler than the approaches used previously. This study will assess whether or not PET/MRI scans can provide useful information about hypoxia in pancreatic cancer. Additionally, a recent study at the Princess Margaret Cancer Centre found varying levels of hypoxia in patients with pancreatic tumors, providing a rationale for incorporating hypoxia imaging and patient-specific treatment adaptation into the clinical management of pancreatic cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04395469
Study type Interventional
Source University Health Network, Toronto
Contact
Status Active, not recruiting
Phase N/A
Start date May 18, 2021
Completion date March 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05679674 - Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer N/A
Recruiting NCT04617821 - AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer Phase 3
Completed NCT03673137 - Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC Phase 2/Phase 3
Recruiting NCT04652206 - Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. Phase 1/Phase 2
Completed NCT02394535 - Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer Phase 1
Not yet recruiting NCT06399172 - OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
Withdrawn NCT03536182 - Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer Phase 3
Active, not recruiting NCT01585805 - Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Recruiting NCT05607953 - Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma Phase 1
Not yet recruiting NCT06381154 - Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer Phase 2
Active, not recruiting NCT03269526 - BATs Treatment for Pancreatic Cancer, Phase Ib/II Phase 1/Phase 2
Not yet recruiting NCT06453486 - A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment Phase 2
Recruiting NCT05524090 - PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
Completed NCT01342224 - Immunochemoradiotherapy in Patients With Pancreatic Cancer Phase 1
Completed NCT01278368 - Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection N/A
Recruiting NCT04172532 - Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer Phase 1/Phase 2
Active, not recruiting NCT04423731 - Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
Not yet recruiting NCT06272162 - Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy N/A
Active, not recruiting NCT00669734 - Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery Phase 1
Recruiting NCT04665947 - First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer Early Phase 1